Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.24.1.1.u2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:    
Research and development $ 2,123,778 $ 3,510,252
General and administrative 1,552,873 1,460,419
Total operating expenses 3,676,651 4,970,671
Loss from operations (3,676,651) (4,970,671)
Other income (expense):    
Change in fair value of financial instruments (14,132) (41,665)
Interest expense (76,775)  
Other income 132,470 52,905
Total other income (expense), net 41,563 11,240
Net loss (3,635,088) (4,959,431)
Other comprehensive loss    
Foreign currency translation adjustment   (4,354)
Comprehensive loss $ (3,635,088) $ (4,963,785)
Net loss per share, basic $ (0.19) $ (0.58)
Net loss per share, diluted $ (0.19) $ (0.58)
Weighted-average shares outstanding of common shares, basic 19,533,976 8,579,284
Weighted-average shares outstanding of common shares, diluted 19,533,976 8,579,284